{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:59:51Z","timestamp":1786132791036,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["Z01 DE000649 25"],"award-info":[{"award-number":["Z01 DE000649 25"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["Zo1 HG000215 17"],"award-info":[{"award-number":["Zo1 HG000215 17"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["DK-67563"],"award-info":[{"award-number":["DK-67563"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["DK-35423"],"award-info":[{"award-number":["DK-35423"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P01 DK011794"],"award-info":[{"award-number":["P01 DK011794"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK046718"],"award-info":[{"award-number":["DK046718"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pontificia Universidad Catolica de Chile"},{"name":"The Oscar & Elsa Braun Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2020,9]]},"abstract":"\n Significance Statement<\/jats:title>\n Most forms of CKD present with well recognized mineral and bone disorders. It is unknown whether a different biochemical pattern of mineral abnormalities is associated with causes of CKD that manifest with persistent tubular phosphate wasting, such as the lysosomal storage disease nephropathic cystinosis. The authors demonstrate that patients with CKD caused by nephropathic cystinosis have mineral abnormalities that are distinct from those in CKD arising from other causes, including significantly lower levels of fibroblast growth factor-23 (FGF23) and percent tubular reabsorption of phosphate. These findings support the notion that phosphate is a significant driver of increased FGF23 levels in CKD and that mineral abnormalities associated with CKD are likely to vary depending on the underlying renal disease.<\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n The rare lysosomal storage disease nephropathic cystinosis presents with renal Fanconi syndrome that evolves in time to CKD. Although biochemical abnormalities in common causes of CKD\u2013mineral and bone disorder have been defined, it is unknown if persistent phosphate wasting in nephropathic cystinosis is associated with a biochemical mineral pattern distinct from that typically observed in CKD\u2013mineral and bone disorder.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We assessed and compared determinants of mineral homeostasis in patients with nephropathic cystinosis across the predialysis CKD spectrum to these determinants in age- and CKD stage-matched patients, with causes of CKD other than nephropathic cystinosis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 50 patients with nephropathic cystinosis-related CDK and 97 with CKD from other causes. All major aspects of mineral homeostasis were differentially effected in patients with CKD stemming from nephropathic cystinosis versus other causes. Patients with nephropathic cystinosis had significantly lower percent tubular reabsorption of phosphate and fibroblast growth factor-23 (FGF23) at all CKD stages, and lower blood phosphate in CKD stages 3\u20135. Linear regression analyses demonstrated lower FGF23 levels in nephropathic cystinosis participants at all CKD stages when corrected for eGFR and age, but not when adjusted for serum phosphate.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Nephropathic cystinosis CKD patients have mineral abnormalities that are distinct from those in CKD stemming from other causes. Persistently increased urinary phosphate excretion maintains serum phosphate levels within the normal range, thus protecting patients with nephropathic cystinosis from elevations of FGF23 during early CKD stages. These findings support the notion that phosphate is a significant driver of increased FGF23 levels in CKD and that mineral abnormalities associated with CKD are likely to vary depending on the underlying renal disease.<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2019111172","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T19:54:38Z","timestamp":1594065278000},"page":"2184-2192","source":"Crossref","is-referenced-by-count":20,"title":["Nephropathic Cystinosis: A Distinct Form of CKD\u2013Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23"],"prefix":"10.1681","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-3146","authenticated-orcid":false,"given":"Pablo","family":"Florenzano","sequence":"first","affiliation":[{"name":"Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, Bethesda, Maryland"},{"name":"Endocrinology Department, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Endocrinology Department, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Nesterova","sequence":"additional","affiliation":[{"name":"Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Scott","family":"Roberts","sequence":"additional","affiliation":[{"name":"Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harsha","family":"Tella","sequence":"additional","affiliation":[{"name":"Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fernandez de Castro","sequence":"additional","affiliation":[{"name":"Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel I.","family":"Gafni","sequence":"additional","affiliation":[{"name":"Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"J\u00fcppner","sequence":"additional","affiliation":[{"name":"Endocrine Unit and Pediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gales","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Wesseling-Perry","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Markovich","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Gahl","sequence":"additional","affiliation":[{"name":"Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Collins","sequence":"additional","affiliation":[{"name":"Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Dental and Craniofacial Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"B1-20231016","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-016-0426-y","article-title":"Cystinosis: A review","volume":"11","author":"Elmonem","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"B2-20231016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMra020552","article-title":"Cystinosis","volume":"347","author":"Gahl","year":"2002","journal-title":"N Engl J Med"},{"key":"B3-20231016","first-page":"94","article-title":"Cystinosis as a lysosomal storage disease with multiple mutant alleles: Phenotypic-genotypic correlations","volume":"2","author":"Al-Haggar","year":"2013","journal-title":"World J Nephrol"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MOP.0000000000000462","article-title":"Nephropathic cystinosis: An update","volume":"29","author":"Veys","year":"2017","journal-title":"Curr Opin Pediatr"},{"issue":"Suppl 4","key":"B5-20231016","doi-asserted-by":"crossref","first-page":"iv87","DOI":"10.1093\/ndt\/gfu090","article-title":"Nephropathic cystinosis: An international consensus document","volume":"29","author":"Emma","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJM199304223281604","article-title":"Improved renal function in children with cystinosis treated with cysteamine","volume":"328","author":"Markello","year":"1993","journal-title":"N Engl J Med"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrneph.2016.182","article-title":"The renal Fanconi syndrome in cystinosis: Pathogenic insights and therapeutic perspectives","volume":"13","author":"Cherqui","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/ki.2011.277","article-title":"Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults","volume":"81","author":"Brodin-Sartorius","year":"2012","journal-title":"Kidney Int"},{"key":"B9-20231016","first-page":"3257","article-title":"Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis","volume":"80","author":"Kimonis","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B10-20231016","doi-asserted-by":"crossref","first-page":"242","DOI":"10.7326\/0003-4819-147-4-200708210-00006","article-title":"Nephropathic cystinosis in adults: Natural history and effects of oral cysteamine therapy","volume":"147","author":"Gahl","year":"2007","journal-title":"Ann Intern Med"},{"key":"B11-20231016","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/jbmr.3522","article-title":"Skeletal consequences of nephropathic cystinosis","volume":"33","author":"Florenzano","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2215\/CJN.05940611","article-title":"Early skeletal and biochemical alterations in pediatric chronic kidney disease","volume":"7","author":"Wesseling-Perry","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2215\/CJN.05840513","article-title":"Disordered FGF23 and mineral metabolism in children with CKD","volume":"9","author":"Portale","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"key":"B15-20231016","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011]","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B16-20231016","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.kint.2016.12.029","article-title":"The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease","volume":"91","author":"Graciolli","year":"2017","journal-title":"Kidney Int"},{"key":"B17-20231016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.21873\/invivo.11038","article-title":"Effect of calcitriol on FGF23 level in healthy adults and its dependence on phosphate level","volume":"31","author":"Georgiadou","year":"2017","journal-title":"In Vivo"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrneph.2014.49","article-title":"Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease","volume":"10","author":"Scialla","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","article-title":"Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease","volume":"6","author":"Moe","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20231016","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ndt\/gfs405","article-title":"Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): Results of a randomized trial","volume":"28","author":"Sigrist","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B21-20231016","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B22-20231016","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients","volume":"26","author":"Gonzalez-Parra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20231016","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/ndt\/gft203","article-title":"A comparison of calcium acetate\/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: Post hoc evaluation from a controlled, randomized study","volume":"28","author":"Covic","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","article-title":"Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease","volume":"26","author":"Isakova","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.09250912","article-title":"Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD","volume":"8","author":"Isakova","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B26-20231016","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1681\/ASN.2018121250","article-title":"Pharmacological Npt2a inhibition causes phosphaturia and reduces plasma phosphate in mice with normal and reduced kidney function","volume":"30","author":"Thomas","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B27-20231016","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B29-20231016","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial","volume":"30","author":"Block","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B30-20231016","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ndt\/gfy061","article-title":"The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia","volume":"34","author":"Block","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B31-20231016","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE trial","volume":"30","author":"Ix","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B32-20231016","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1021\/acsmedchemlett.8b00013","article-title":"Discovery of orally bioavailable selective inhibitors of the sodium-phosphate cotransporter NaPi2a (SLC34A1)","volume":"9","author":"Filipski","year":"2018","journal-title":"ACS Med Chem Lett"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2019111172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:24:08Z","timestamp":1786130648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2019111172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2019111172","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}